Iterum Therapeutics plc

NasdaqCM ITRM

Iterum Therapeutics plc Net Income for the year ending December 31, 2023: USD -38.37 M

Iterum Therapeutics plc Net Income is USD -38.37 M for the year ending December 31, 2023, a 13.64% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Iterum Therapeutics plc Net Income for the year ending December 31, 2022 was USD -44.43 M, a 51.47% change year over year.
Iterum Therapeutics plc Net Income for the year ending December 31, 2021 was USD -91.56 M, a -76.06% change year over year.
Iterum Therapeutics plc Net Income for the year ending December 31, 2020 was USD -52.01 M, a 49.57% change year over year.
Iterum Therapeutics plc Net Income for the year ending December 31, 2019 was USD -103.13 M, a -33.84% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: ITRM

Iterum Therapeutics plc

CEO	Mr. Corey N. Fishman
IPO Date	May 25, 2018
Location	Ireland
Headquarters	Fitzwilliam Court
Employees	14
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years